Search
Inhibikase Therapeutics Inc
IKTAdd to Watchlist
2.330USD
+0.160+7.37%
Close 07-23 16:00（ET）Quotes delayed by 15 min
307.64MMarket Cap
LossP/E TTM
More Details of Inhibikase Therapeutics Inc Company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc Info
Ticker SymbolIKT
Company nameInhibikase Therapeutics Inc
IPO dateDec 23, 2020
CEOIwicki (Mark T)
Number of employees15
Security typeOrdinary Share
Fiscal year-endDec 23
Address1000 N. West Street, Suite 1200
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19801
Phone13022953800
Websitehttps://www.inhibikase.com/
Ticker SymbolIKT
IPO dateDec 23, 2020
CEOIwicki (Mark T)
Company Executives of Inhibikase Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
--
-100.00%
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Inhibikase Therapeutics Inc?
The top five shareholders of Inhibikase Therapeutics Inc are: Dr. Christopher H. (Chris) Cabell, M.D.
How many institutions hold shares of Inhibikase Therapeutics Inc (IKT)?
As of 2026Q1, 152 institutions hold shares of Inhibikase Therapeutics Inc, with a combined market value of approximately 103.21M, accounting for 78.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 43845693.00.